Targeting Mcl-1 to treat lung cancer
Modulation of Mcl-1 for Treatment of Lung Cancer
This study is looking at how changes in a gene called KRAS affect a protein linked to lung cancer, and it aims to create a new drug that could help treat lung cancer patients, even if they don't have certain genetic mutations, by working alongside an existing cancer medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11086862 on NIH RePORTER |
What this research studies
This research investigates how mutations in the KRAS gene affect the stability of a protein called Mcl-1, which plays a role in lung cancer progression. By understanding the mechanisms that stabilize Mcl-1, the researchers aim to develop a new class of drugs, specifically a small molecule inhibitor called MI-223, that can effectively target and inhibit Mcl-1's function. The study also explores the potential of combining MI-223 with an existing cancer drug, olaparib, to enhance treatment efficacy for lung cancer patients, even those without specific genetic mutations. Patients may benefit from this innovative approach to lung cancer therapy, which could lead to improved outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include lung cancer patients, particularly those with KRAS mutations or those who have not responded to existing therapies.
Not a fit: Patients with lung cancer who do not have KRAS mutations or who are not eligible for experimental treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for lung cancer patients, potentially improving survival rates and treatment responses.
How similar studies have performed: Other research has shown promising results with similar approaches targeting Mcl-1 and combining therapies, indicating potential for success in this area.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Deng, Xingming — Emory University
- Study coordinator: Deng, Xingming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.